Why Hedge Fund Bets Make UNH Healthcare's Hottest Turnaround Play[Stocks](https://moneymorning.com/category/article/stocks/) # Why Hedge Fund Bets Make UNH Healthcare's Hottest Turnaround Play  by Rich Duprey  November 26, 2025  Share it: ## Here's Why UnitedHealth Group Is Ready to Soar **UnitedHealth Group** ( [UNH](https://moneymorning.com/stocks/unh/)) has staged a remarkable recovery from its August lows that followed a brutal year of regulatory scrutiny, cyberattack disruptions, Medicare reimbursement cuts, and an executive assassination. Once a Wall Street darling, the stock stumbled amid these headwinds, erasing gains and testing investor patience. Yet, amid the rubble, UNH emerges as the most undervalued gem in healthcare – a sector brimming with innovation and demographic tailwinds. Trading at levels unseen since 2020-2021, this could mark the inflection point: a convergence of smart money inflows, resilient fundamentals, and bargain pricing that catapults UNH shares into a soaring trajectory, rewarding long-term believers with outsized returns. ## Hedge Funds Are Fueling Healthcare's Surge Hedge funds are suddenly swarming into healthcare stocks, spearheading a bold market rotation from overhyped AI plays to defensive stalwarts. According to a recent _Bloomberg_ report, this shift has propelled the **S&P 500 Health Care Index** up 10% through Tuesday – outpacing all other sectors while the broader **S&P 500** dipped 1.1% in the same stretch. Funds, burned by tech volatility, are reallocating billions into the sector's stability and growth potential, betting on an aging population and biotech breakthroughs to drive sustained gains.  ## The Undervalued Breakout Contender While sector leaders like **Eli Lilly** ( [LLY](https://moneymorning.com/stocks/lly/)) steal headlines with a blistering 29% rally – pushing it past the $1 trillion mark – and **Merck** ( [MRK](https://moneymorning.com/stocks/mrk/)) climbs 18% on oncology momentum, UNH lurks as the sleeper hit primed for explosive upside. **Regeneron Pharmaceuticals** ( [REGN](https://moneymorning.com/stocks/regn/)) and **Biogen** ( [BIIB](https://moneymorning.com/stocks/biib/)) have notched similar double-digit surges, but UNH's scale as America's largest health insurer positions it for outsized leverage in this rotation. With 50 million Optum members and a sprawling pharmacy benefits arm, UnitedHealth is the backbone of U.S. healthcare delivery, insulating it from pure-play drug risks while capitalizing on rising premiums and value-based care trends. The stock's long-term potential is staggering: analysts project 12% to 15% annual earnings growth through 2030, fueled by Medicare expansion and AI-driven cost efficiencies. At a forward P/E of 18x – versus the S&P 500's 22x and healthcare peers' 20x average – UNH offers value. Its price-to-sales ratio of 0.9x further underscores the bargain, [trading below historical norms](https://moneymorning.com/2025/10/28/unitedhealth-unh-recovery-continues-beats-earnings-raises-outlook/) and even cheaper than during the pandemic dip. Back at 2020-2021 price levels around $325, a modest multiple expansion to the industry average could ignite 50%+ gains, sending shares toward $500 by year-end 2026. This isn't blind optimism; it's arithmetic backed by momentum. As hedge funds pile in, UNH's free cash flow of $20 billion annually supports aggressive buybacks and dividends, yielding 2.6%. In a rotation favoring resilience over speculation, UnitedHealth isn't just participating; it's leading the charge. For investors eyeing the next decade's healthcare boom, UNH represents not recovery, but reinvention – and a stock ready to soar. **Beat the market, without relying on brokers or biased institutions.** Email(Required) Company This field is for validation purposes and should be left unchanged. Subscribe By submitting your email address, you will receive a free subscription to _Money Morning!_ and occasional special offers from us and our affiliates. You can unsubscribe at any time and we encourage you to read more about our [Privacy Policy](https://moneymorning.com/privacy/). ## One moment, please: Processing your submission ###### More Trending Stories from Money Morning - [Here's Why ACM Research Is a Buy Despite Its Earnings Miss](https://moneymorning.com/2026/03/01/why-acm-research-is-a-buy-despite-earnings/) - [$10,000 Invested in MercadoLibre 5 Years Ago Would Be How Much?!](https://moneymorning.com/2026/02/27/10000-invested-in-mercadolibre-5-years-ago-would-be-how-much/) - [Is a Buyout the Hope PayPal Investors Have Been Waiting For?](https://moneymorning.com/2026/02/27/is-a-buyout-the-hope-paypal-investors-have-been-waiting-for/) - [Here's Why ACM Research Is a Buy Despite Its Earnings Miss](https://moneymorning.com/2026/02/27/heres-why-acm-research-is-a-buy-despite-earnings/) - [Axon Enterprise Stuns the Market With Huge Q4 Earnings Beat](https://moneymorning.com/2026/02/27/axon-enterprise-stuns-the-market-with-huge-q4-earnings-beat/) Share it: ### Popular Articles ###### [Here's Why ACM Research Is a Buy Despite Its Earnings Miss](https://moneymorning.com/2026/03/01/why-acm-research-is-a-buy-despite-earnings/) March 1, 2026 ###### [$10,000 Invested in MercadoLibre 5 Years Ago Would Be How Much?!](https://moneymorning.com/2026/02/27/10000-invested-in-mercadolibre-5-years-ago-would-be-how-much/) February 27, 2026 ###### [Here's Why ACM Research Is a Buy Despite Its Earnings Miss](https://moneymorning.com/2026/02/27/heres-why-acm-research-is-a-buy-despite-earnings/) February 27, 2026 ###### [Axon Enterprise Stuns the Market With Huge Q4 Earnings Beat](https://moneymorning.com/2026/02/27/axon-enterprise-stuns-the-market-with-huge-q4-earnings-beat/) February 27, 2026 Notifications reCAPTCHA Recaptcha requires verification. [Privacy](https://www.google.com/intl/en/policies/privacy/) \- [Terms](https://www.google.com/intl/en/policies/terms/) protected by **reCAPTCHA** [Privacy](https://www.google.com/intl/en/policies/privacy/) \- [Terms](https://www.google.com/intl/en/policies/terms/)